Competition heats up in PNH with new Roche data

Positive Phase III results from Genentech’s crovalimab further build the case for the C5 inhibitor to challenge established paroxysmal nocturnal hemoglobinuria therapies.

Data from the global COMMODORE 2 trial showed that crovalimab achieved disease control when administered subcutaneously every four weeks, and was not inferior to Soliris eculizumab, the current standard of care, which is delivered intravenously every two weeks. The anti-C5 mAb met its co-primary endpoints of transfusion avoidance and control of hemolysis. ...